BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/20/2020 2:28:50 AM | Browse: 796 | Download: 1728
 |
Received |
|
2020-02-14 06:21 |
|
Peer-Review Started |
|
2020-02-14 06:23 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-28 21:09 |
|
Revised |
|
2020-06-02 09:44 |
|
Second Decision |
|
2020-06-10 08:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-06-10 19:51 |
|
Articles in Press |
|
2020-06-10 19:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-07-17 02:04 |
|
Publish the Manuscript Online |
|
2020-07-20 02:28 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuri Ozaki, Akiyo Yoshimura, Masataka Sawaki, Masaya Hattori, Naomi Gondo, Haruru Kotani, Yayoi Adachi, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuka Endo, Kazuki Nozawa, Shoko Sakamoto and Hiroji Iwata |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yuri Ozaki, MD, Surgical Oncologist, Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 kanoko-den chikusa-ku Nagoya City, Aichi, Nagoya 464-8681, Japan. yozaki@aichi-cc.jp |
| Key Words |
Breast cancer; Lung metastasis; Bevacizumab; Adverse event; Pneumothorax; Case report |
| Core Tip |
Combination therapy with Bevacizumab and chemotherapy is used to expect its high antitumor effect. However, Bevacizumab-containing combination therapies can induce severe adverse events. Mechanisms and risk factors that underlie the onset of pneumothorax are not clear. Here, we report a case of pneumothorax associated with a combination therapy of Bevacizumab with chemotherapy, and discuss the mechanisms and risk factors. Patients with multiple lung metastases surrounding the bronchi and on the pleura, should be monitored for pneumothorax, an adverse event that can be induced by the rapid necrosis due to Bevacizumab-containing combination chemotherapies. |
| Publish Date |
2020-07-20 02:28 |
| Citation |
Ozaki Y, Yoshimura A, Sawaki M, Hattori M, Gondo N, Kotani H, Adachi Y, Kataoka A, Sugino K, Horisawa N, Endo Y, Nozawa K, Sakamoto S, Iwata H. Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report. World J Clin Oncol 2020; 11(7): 504-509 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i7/504.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i7.504 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
